MetaCap

Korsana Biosciences Cash Flow Statement

NASDAQ: KRSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

33.92+0.41 (+1.22%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Korsana Biosciences free cash flow

In fiscal 2025, Korsana Biosciences generated -$3.3 million of operating cash flow. That left free cash flow of -$3.3 million, a free-cash-flow margin of -159.8% of revenue.

Summary generated from market data by MetaCap's automated system. Methodology

Korsana Biosciences cash flow statement (annual)

Korsana Biosciences annual cash flow statement
Fiscal year (USD)FY 20252025-12-31FY 20242024-12-31FY 20232023-12-31FY 20222022-12-31FY 20212021-12-31FY 20202020-12-31FY 20192019-12-31FY 20182018-12-31
Net Income-3.53M-3.06M-5.26M-44.08M-51.65M-77.80M-123.01M-115.25M
Net Income growth (YoY)————————
Depreciation & Amortization——065.00K472.00K2.30M2.70M1.53M
Stock-Based Compensation441.00K625.00K1.07M6.25M9.61M14.99M19.63M12.43M
Change in Working Capital-326.00K-1.00M-1.68M1.15M579.00K-1.30M-331.00K979.00K
Operating Cash Flow-3.31M-4.33M-21.25M-40.61M-36.52M-72.49M-102.22M-97.50M
Capital Expenditures———0-7.00K-1.52M-6.89M-3.44M
Investing Cash Flow—010.40M01.46M18.00K-6.71M-3.44M
Financing Cash Flow3.32M05.02M29.00K30.79M28.09M211.57M100.94M
Net Change in Cash8.00K-4.34M-5.81M-40.58M-4.27M-44.39M102.62M124.76M
Free Cash Flow-3.31M-4.33M-21.25M-40.61M-36.52M-74.01M-109.10M-100.94M

This table shows 8 annual periods of Korsana Biosciences's cash flow statement, from FY 2025 back to FY 2018, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow KRSA's reporting calendar. What is a cash flow statement?

More financial data